Celgene, Acceleron begin midstage trial of bone-loss drug

10/16/2008 | American City Business Journals

Celgene and Acceleron Pharma said they have started a Phase II study of ACE-011, a drug candidate designed to treat bone loss in patients with multiple myeloma and other cancers. Acceleron is getting a $5 million milestone payment from Celgene under a collaboration agreement announced in February.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN